Literature DB >> 12064362

Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow.

Juliet N Barker1, Timothy P Krepski, Todd E DeFor, Stella M Davies, John E Wagner, Daniel J Weisdorf.   

Abstract

Unrelated donor (URD) umbilical cord blood (UCB) has several potential advantages over URD BM for hematopoietic stem cell transplantation. To examine the efficiency of donor identification for each of these URD stem cell sources, we reviewed the search processes for all pediatric and adult URD transplantation referrals to the University of Minnesota during a period of 1 year. Of 171 consecutive referrals for URD transplantation, 108 patients proceeded to a formal URD search with selection of at least 1 donor. Significantly more formal UCB searches(54%) than BM searches (21%) were performed for patients who required urgent transplantation (P < .01). At least one 4-6/6 HLA-antigen matched UCB graft but no suitable BM graft was identified for 21 of the 108 patients (19%). The median time required to obtain a URD BM donor (from formal search to clearance of a BM donor) was 49 days (range, 32-293 days) compared to a UCB search time (from formal search to a donor unit chosen) of only 13.5 days (range, 2-387 days). For patients undergoing both BM and UCB searches, 29 more days (95% confidence interval, 21-37 days) were required to identify and clear a URD BM donor than a UCB donor (P < .01). For the 76 patients who proceeded to transplantation, patients receiving UCB received a transplant a median of 25 days more rapidly than did those receiving BM (P < .01). These data confirm that the availability of banked cryopreserved URD UCB grafts allows transplantations for patients with no available BM donor and that URD UCB grafts areavailable considerably faster than are URD BM grafts. Faster availability is a particular advantage for patients requiring urgent transplantation. These unique features of UCB transplantation must be considered in comparisons of the outcomes of UCB versus BM transplant recipients and in the design of prospective trials comparing URD sources.

Entities:  

Mesh:

Year:  2002        PMID: 12064362     DOI: 10.1053/bbmt.2002.v8.pm12064362

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  46 in total

Review 1.  Double cord blood transplants: filling a niche?

Authors:  Richard L Haspel; Karen K Ballen
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

2.  HLA-identical umbilical cord blood transplantation from a sibling donor in juvenile myelomonocytic leukemia.

Authors:  Andrica C H de Vries; Robbert G M Bredius; Arjan C Lankester; Marc Bierings; Monika Trebo; Petr Sedlacek; Charlotte M Niemeyer; Marco Zecca; Franco Locatelli; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

Review 3.  Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Authors:  H J Symons; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-08-04       Impact factor: 5.483

Review 4.  Cord blood transplantation: state of the art.

Authors:  Eliane Gluckman; Vanderson Rocha
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

5.  Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search.

Authors:  A A Hamidieh; M Ostadali Dehaghi; P Paragomi; S Navaei; A Jalali; G Ghazizadeh Eslami; M Behfar; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

Review 6.  Graft versus host disease: clinical evaluation, diagnosis and management.

Authors:  Edgar M Espana; Sejal Shah; Marcony R Santhiago; Arun D Singh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-17       Impact factor: 3.117

Review 7.  Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia.

Authors:  Melhem Solh
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

8.  Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.

Authors:  Claudio G Brunstein; Daniel J Weisdorf; Todd DeFor; Juliet N Barker; Jakub Tolar; Jo-Anne H van Burik; John E Wagner
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

9.  Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.

Authors:  Sameem Abedin; Edward Peres; John E Levine; Sung Choi; Gregory Yanik; Daniel R Couriel
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-18       Impact factor: 5.742

10.  Outcomes of strategic alternative donor selection or suspending donor search based on Japan Marrow Donor Program coordination status.

Authors:  Naomi Kawashima; Satoshi Nishiwaki; Naoko Shimizu; Sonoko Kamoshita; Kyoko Watakabe; Emi Yokohata; Shingo Kurahashi; Yukiyasu Ozawa; Koichi Miyamura
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.